PHILADELPHIA, Aug. 12, 2010 — Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).
ANNA members are encouraged to invite Congressional delegations, Centers for Medicare and Medicaid Services (CMS) staff, ESRD regional office staff, and local and regulatory agency staff to visit a local dialysis facility, transplant center, or KEEP program during Kidney Disease Awareness and Education Week. The objective of these visits is to educate policymakers about kidney disease, treatment options, and the legislative issues facing the renal community.
In this regard, Kibow is also a proud participant and contributor to R&D of the maintenance of a healthy kidney function. The company's flagship product, Kibow(R) Biotics, utilizes a patented and proprietary bowel-based enteric technology concept for use in worldwide clinical applications towards maintaining a healthy kidney function.
Kibow has recently completed a pilot-scale study with a limited number of patients in USA, Canada, Argentina and Nigeria. The positive outcome from this study will be published in the peer-reviewed "Advances in Therapy" publication. This report, titled "Pilot Study of Probiotic Dietary Supplementation for Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease," can be accessed freely online in the coming month at either our website (http://www.kibow.com) or the journal's website (http://www.advancesintherapy.com).
Dr. Natarajan Ranganathan, Interim CEO and VP Research and Development, stated, "By offering an affordable, readily available and easy-to-administer dietary supplement product in the USA, Kibow aims to make Kibow(R) Biotics accessible to all those who suffer from kidney problems in other countries worldwide according to individual countries' governmental regulatory/registration authorities."
About Kibow Biotech:
Kibow Biotech, Inc. is a twelve-year-old R&D biotechnology company having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product, called "Kibow(R) Biotics," is an orally consumable, enteric-coated Gel Cap product formulation that is composed of food grade microbes ("Probiotics"), which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.
Forward-looking statements:
Kibow(R) Biotics or any other dietary supplement is not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, contact:
or please visit:
If you have any questions or comments regarding Kidney Disease Awareness and Education (KDAE) Week, contact Email.
Contact:
Natarajan Ranganathan, Ph.D.
Interim CEO and Senior VP (R&D)
Tel: 1 (610) 353 5130
Website: http://www.kibow.com
# # #